XML 22 R10.htm IDEA: XBRL DOCUMENT v3.26.1
Segment Information
 3 Months Ended
Mar. 31, 2026
Segment Reporting [Abstract]  
Segment Information

3. Segment Information

 

The Company’s chief operating decision maker (“CODM”) has been identified as the Company’s Chief Executive Officer (“CEO”). The Company’s CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently has a single operating segment which is comprised of the consolidated financial results of the Company.

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in research and development costs for the three months and March 31, 2026 and 2025.

Schedule of Information by Segment 

   2026   2025 
   Three Months Ended 
   March 31, 
   2026   2025 
Clinical and related oversight costs  $309,794   $15,868 
Preclinical research focused on development of additional novel anti-cancer compounds   23,582    42,770 
Regulatory service costs   -    32,819 
Total research and development costs  $333,376   $91,457 

 

 

The following table presents a summary of research and development costs for the three months ended March 31, 2026 and 2025 based on the respective geographical regions where such costs were incurred.

 

   2026   2025 
   Three Months Ended 
   March 31, 
   2026   2025 
United States  $38,972   $58,571 
Spain   294,404    32,886 
Total  $333,376   $91,457 

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in general and administrative costs for the three months ended March 31, 2026 and 2025.

 

   2026   2025 
   Three Months Ended 
   March 31, 
   2026   2025 
Compensation:           
Cash based compensation 

$

213,434  

$

108,731 
Stock-based compensation   82,176    99,738 
Patent and licensing legal and filing fees and costs   35,032    56,084 
Marketing and public relations   

481,900

    - 
Accounting and bookkepping services   

254,744

    

41,909

 
Audit and legal   

195,846

    

134,103

 
Consulting fees   

181,856

    

29,303

 
Insurance expense   64,387    64,277 
Other costs and expenses, net   

144,656

    81,338 
Total general and administrative costs  $1,654,031   $615,483